
LATEST news

A study on the impact and opportunities of Covid-19 for startups
The Covid-19 crisis has a huge impact on startups. STATION F released the results of the study on the impact of the crisis on startups. Karista, alongside with more than 120 VCs and about 1000 startups, participated.
READ MORE
2020 will be the global kick-off of 5G
A technical and regulatory feat that has enabled everyone to agree on a single standard. 5G is not only a telecom standard: it is also a challenge for the competitiveness of companies in a globalized environment. A company operating in a country that has not deployed 5G will be less efficient than its foreign competitors...
READ MORE
Two portfolio companies integrated FT120
This program is dedicated to startups in the hyper-growth phase. It offers unprecedented support to 123 fast-growing companies. We are very proud to announce that two of our portfolio companies appear in the FT120: TISSIUM and Acticor Biotech
READ MORE
Eyevensys closes a $30M Series B funding round
Eyevensys has completed a $30M Series B financing round. The tour was led by Boehringer Ingelheim Venture Fund and included participation from Karista, Pontifax, Bpifrance, Inserm Transfert, and Global Health Sciences.
READ MORE
Sevenhugs raises an additional $9M
After a first round of $1.7M and a second of $14.6M from CapDecisif Management, Xerys Capital, NovX, and various business angels, the company raised an additional $9M. This financing will allow the company to further develop and distribute their smart home solutions both in the U.S. and globally.
READ MORE
Proptech new actor UpFactor raises €2.5m
UpFactor uses smart data to support owners in their real estate optimization. The company is a highly impactful PropTech contributing to build the city of tomorrow: energy transition and soft densification of our cities thanks to building elevation.
READ MORE
TISSIUM closes a massive €39m Series B funding round
Life sciences company TISSIUM raised 38,75M€ in a Series B funding round. The funding will mainly be used to support the global expansion of the company’s platform of polymers across a variety of therapeutic fields.
READ MORE